Veru Receives Positive Input from FDA on Phase III Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

0
38
Veru Inc. announced that it has received regulatory clarity from the FDA on the pivotal Phase III trial design for VERU-111—its oral, first-in-class, novel alpha and beta tubulin targeting drug candidate being evaluated for the treatment of metastatic castration and novel androgen-blocking agent resistant prostate cancer.
[Veru Inc.]
Press Release